AstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average of $11,299.39

Shares of AstraZeneca PLC (LON:AZNGet Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of £112.99 ($140.54) and traded as high as £121.86 ($151.57). AstraZeneca shares last traded at £120.34 ($149.68), with a volume of 1,381,910 shares traded.

Analyst Ratings Changes

AZN has been the topic of a number of research analyst reports. Jefferies Financial Group set a £108 ($134.33) target price on AstraZeneca in a report on Thursday, February 9th. Guggenheim dropped their price target on AstraZeneca from £127 ($157.96) to £119 ($148.01) in a research report on Tuesday, April 11th. Morgan Stanley raised AstraZeneca to an “overweight” rating in a research report on Tuesday, April 11th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Monday, May 15th. Finally, The Goldman Sachs Group set a GBX 6,950 ($86.44) price target on AstraZeneca in a research report on Thursday, February 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of £119.32 ($148.41).

AstraZeneca Price Performance

The firm has a market capitalization of £186.53 billion, a P/E ratio of 4,993.36, a PEG ratio of 2.32 and a beta of 0.18. The company has a debt-to-equity ratio of 90.68, a quick ratio of 0.59 and a current ratio of 0.90. The firm has a 50-day moving average of £116.43 and a 200-day moving average of £112.99.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Michel Demare acquired 2,000 shares of the stock in a transaction that occurred on Friday, April 28th. The shares were acquired at an average cost of £117.01 ($145.53) per share, with a total value of £234,020 ($291,069.65). 0.23% of the stock is currently owned by insiders.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.